How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing
Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.
Can non-viral gene therapies solve the safety problem holding back genetic medicine?
Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.